AXIM BIOTECHNOLOGIES INC - AXIM STOCK NEWS

AXIM Biotechnologies' commercialization partner, Verséa Ophthalmic, places a re-stock order for AXIM's digital assay reader, indicating a growing clinical presence and revenue opportunity. The order reflects successful clinical validation and an impending expansion of AXIM's diagnostic program.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) has signed a contract manufacturing agreement with Auer Precision to scale production of its FDA-cleared diagnostic assays for Dry Eye Disease. The partnership aims to meet the growing demand for the tests in a cost-effective way, enabling AXIM to focus on research and development.

AXIM develops rapid diagnostic assay for Parkinson's Disease biomarker

AXIM Biotechnologies, Inc. (OTCQB: AXIM) announces the expansion of its IP portfolio with 13 filings and allowances, covering a wide range of diagnostic solutions including SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9, and cancer biomarkers. The USPTO has granted patents for COVID-19 neutralizing antibody testing, rapid diagnostics for cancers, and point-of-care cancer detection methods, enhancing the company's value proposition and market potential.

AXIM Biotechnologies has commenced the manufacturing of its proprietary Ocular Immunoglobulin E (IgE) and Lactoferrin diagnostic tests, fulfilling orders from its commercialization partner. The company is producing three separate lots of each assay with a monthly capacity of up to 25,000 units. These point-of-care tests deliver results in just eight minutes and can quantify IgE and Lactoferrin levels, aiding in the diagnosis and treatment of dry eye disease (DED). Approximately 344 million people globally are affected by DED, highlighting the demand for effective diagnostic tools. AXIM's ability to manufacture in-house enhances its quality control and profit margins. This milestone positions AXIM for a more rapid market entry of its diagnostic products and supports its ongoing collaboration with clinicians.

AXIM Biotechnologies has filed a provisional patent with the U.S. Patent and Trademark Office for a proprietary methodology in ocular diagnostic assays. This innovation enables the use of a significantly reduced tear sample size, improving the accuracy and usability of diagnostic tests. Most tests require a tear sample of about 10 microliters, while AXIM’s method only requires 1 microliter, enhancing test sensitivity and specificity. The company plans to integrate this technique into commercially available tests soon. AXIM is also focused on rapid diagnostic solutions for conditions like Dry Eye Disease, an area affecting millions of Americans.